There is no earnings read to make from the supplied material. The 8-K cover filing only says BioCryst issued a second-quarter 2026 results release on August 5 and incorporates it as Exhibit 99.1; it contains none of the release’s revenue, earnings, cash, guidance, ORLADEYO sales, or pipeline-update details. (Item 2.02; Exhibit index)
That prevents a defensible beat-or-miss conclusion. Published pre-report estimates appeared to center around roughly $183 million–$188 million of revenue and about $0.12–$0.15 EPS, but the supplied filing provides no actual figures to compare against them. Calling this positive, negative, or even in line would be invention rather than analysis.
The only new information visible here is procedural, not economic. This is a standard results-announcement 8-K that furnishes, rather than files, the missing press release under Items 2.02 and 7.01. The substantive exhibit is required to determine what changed versus market expectations. (Items 2.02, 7.01; Exhibit 99.1)
Read the original 8-K on SEC EDGAR ↗